替沙基奥仑赛与标准治疗在侵袭性B细胞淋巴瘤二线治疗中的对比
这项国际3期试验纳入322例对一线治疗难治或12个月内进展的侵袭性淋巴瘤患者,随机接受替沙基奥仑赛(可选桥接治疗)或挽救化疗联合自体造血干细胞移植。两组中位无事件生存期均为3.0个月(HR 1.07,95%CI 0.82-1.40,P=0.61),替沙基奥仑赛不优于标准挽救治疗,需进一步研究评估哪些患者可从各方案中最大获益。
要点
- 替沙基奥仑赛组与标准治疗组中位无事件生存期均为3.0个月,HR 1.07(95%CI 0.82-1.40,P=0.61)。
- 替沙基奥仑赛组46.3%与标准治疗组42.5%的患者出现缓解。
- 替沙基奥仑赛组10例、标准治疗组13例死于不良事件。
核心结论
- 在本试验中,替沙基奥仑赛不优于标准挽救治疗。
- 需要进一步研究以评估哪些患者可能从每种方案中获得最大获益。
研究设计与样本
- 国际3期试验,纳入对一线治疗难治或12个月内进展的侵袭性淋巴瘤患者,共322例随机分组。
- 患者随机接受替沙基奥仑赛联合可选桥接治疗(替沙基奥仑赛组)或挽救化疗联合自体造血干细胞移植(标准治疗组)。
- 主要终点为无事件生存期,定义为从随机化至第12周评估时或之后出现疾病稳定或进展或死亡的时间。
- 若在第12周评估时或之后发生定义的事件,允许交叉接受替沙基奥仑赛。
主要发现
- 基线时替沙基奥仑赛组高级别淋巴瘤比例高于标准治疗组(24.1% vs 16.9%),国际预后指数评分≥2的比例也更高(65.4% vs 57.5%)。
- 替沙基奥仑赛组95.7%的患者接受了替沙基奥仑赛;标准治疗组32.5%的患者接受了自体造血干细胞移植。
- 从白细胞分离至替沙基奥仑赛输注的中位时间为52天。
- 第6周时替沙基奥仑赛组25.9%的患者出现淋巴瘤进展,标准治疗组为13.8%。
- 两组中位无事件生存期均为3.0个月,替沙基奥仑赛组事件或死亡的风险比为1.07(95%CI 0.82-1.40,P=0.61)。
关键数值与推荐
- 替沙基奥仑赛组缓解率为46.3%,标准治疗组为42.5%。
- 替沙基奥仑赛组10例患者死于不良事件,标准治疗组13例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需要进一步研究以评估哪些患者可能从每种方案中获得最大获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patient outcomes are poor for aggressive B-cell non-Hodgkin's lymphomas not responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an anti-CD19 chimeric antigen receptor T-cell therapy approved for diffuse large B-cell lymphoma after at least two treatment lines. METHODS: We conducted an international phase 3 trial involving patients with aggressive lymphoma that was refractory to or progressing within 12 months after first-line therapy. Patients were randomly assigned to receive tisagenlecleucel with optional bridging therapy (tisagenlecleucel group) or salvage chemotherapy and autologous hematopoietic stem-cell transplantation (HSCT) (standard-care group). The primary end point was event-free survival, defined as the time from randomization to stable or progressive disease at or after the week 12 assessment or death. Crossover to receive tisagenlecleucel was allowed if a defined event occurred at or after the week 12 assessment. Other end points included response and safety. RESULTS: A total of 322 patients underwent randomization. At baseline, the percentage of patients with high-grade lymphomas was higher in the tisagenlecleucel group than in the standard-care group (24.1% vs. 16.9%), as was the percentage with an International Prognostic Index score (range, 0 to 5, with higher scores indicating a worse prognosis) of 2 or higher (65.4% vs. 57.5%). A total of 95.7% of the patients in the tisagenlecleucel group received tisagenlecleucel; 32.5% of the patients in the standard-care group received autologous HSCT. The median time from leukapheresis to tisagenlecleucel infusion was 52 days. A total of 25.9% of the patients in the tisagenlecleucel group had lymphoma progression at week 6, as compared with 13.8% of those in the standard-care group. The median event-free survival in both groups was 3.0 months (hazard ratio for event or death in the tisagenlecleucel group, 1.07; 95% confidence interval, 0.82 to 1.40; P = 0.61). A response occurred in 46.3% of the patients in the tisagenlecleucel group and in 42.5% in the standard-care group. Ten patients in the tisagenlecleucel group and 13 in the standard-care group died from adverse events. CONCLUSIONS: Tisagenlecleucel was not superior to standard salvage therapy in this trial. Additional studies are needed to assess which patients may obtain the most benefit from each approach. (Funded by Novartis; BELINDA ClinicalTrials.gov number, NCT03570892.).
引用
- Bishop MR, Dickinson M, Purtill D, et al. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med. 2021. PMID: 34904798. doi:10.1056/NEJMoa2116596
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。